List of Ilevro drug patents

Ilevro is owned by Novartis.

Ilevro contains Nepafenac.

Ilevro has a total of 3 drug patents out of which 0 drug patents have expired.

Ilevro was authorised for market use on 16 October, 2012.

Ilevro is available in suspension/drops;ophthalmic dosage forms.

The generics of Ilevro are possible to be released after 31 March, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers
Jun, 2024

(1 year, 4 months from now)

US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions
Dec, 2030

(7 years from now)

US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic